Pleco’s team is working strenuously on the development of the PlecoidTM agents to increase the survival rate of patients with AML which is a disease carrying a poor prognosis.

September is Blood Cancer Awareness month which is an opportunity for Pleco to talk about the support the company aims to provide to 382,000 patients diagnosed with AML every year in the world.

Leave a Reply

Your email address will not be published. Required fields are marked *